Top Markets
Coin of the day
Zenas BioPharma, Inc. Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIO
Rang în acțiuni #6395
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm,... Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Preț acțiune
$33.00
Capitalizare de piață
$2.08B
Schimbare (1 zi)
-0.12%
Schimbare (1 an)
97.49%
Țară
US
Tranzacționează Zenas BioPharma, Inc. (ZBIO)

Categorie

Raport P/B pentru Zenas BioPharma, Inc. (ZBIO)
Raport P/B la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Zenas BioPharma, Inc., raportul P/B actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/B de 0.
Istoricul raportului P/B pentru Zenas BioPharma, Inc. din 2026 până în 2026
Raport P/B la sfârșitul fiecărui an
An Raport P/B Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raport P/B pentru companii similare sau competitoare
Companie Raport P/B Diferență raport P/B Țara
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH